Stem definition | Drug id | CAS RN |
---|---|---|
monobactam antibiotics | 279 | 78110-38-0 |
Dose | Unit | Route |
---|---|---|
0.23 | g | Inhal.solution |
4 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 68 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 305.44 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 1 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.18 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.40 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.50 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 21, 2009 | EMA | GILEAD SCIENCES IRELAND UC | |
Dec. 31, 1986 | FDA | BRISTOL MYERS SQUIBB |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Infective pulmonary exacerbation of cystic fibrosis | 1732.65 | 24.19 | 363 | 7973 | 8454 | 63472232 |
Cystic fibrosis | 418.16 | 24.19 | 95 | 8241 | 3201 | 63477485 |
Death | 254.26 | 24.19 | 277 | 8059 | 374104 | 63106582 |
Lung transplant | 229.73 | 24.19 | 58 | 8278 | 3070 | 63477616 |
Pulmonary function test decreased | 216.35 | 24.19 | 58 | 8278 | 3889 | 63476797 |
Haemoptysis | 212.55 | 24.19 | 94 | 8242 | 28632 | 63452054 |
Hospitalisation | 201.07 | 24.19 | 130 | 8206 | 84951 | 63395735 |
Bacterial disease carrier | 194.02 | 24.19 | 43 | 8293 | 1288 | 63479398 |
Bronchial secretion retention | 181.94 | 24.19 | 47 | 8289 | 2726 | 63477960 |
Superinfection | 160.46 | 24.19 | 42 | 8294 | 2565 | 63478121 |
Eosinophilia | 144.61 | 24.19 | 67 | 8269 | 22689 | 63457997 |
Pseudomonas infection | 131.42 | 24.19 | 51 | 8285 | 11162 | 63469524 |
Cystic fibrosis respiratory infection suppression | 129.89 | 24.19 | 24 | 8312 | 277 | 63480409 |
Bronchospasm | 116.43 | 24.19 | 53 | 8283 | 17227 | 63463459 |
Respiratory failure | 115.01 | 24.19 | 100 | 8236 | 101758 | 63378928 |
Sinus operation | 113.87 | 24.19 | 32 | 8304 | 2554 | 63478132 |
Scoliosis | 103.63 | 24.19 | 39 | 8297 | 7849 | 63472837 |
Sleep disorder due to a general medical condition | 96.93 | 24.19 | 42 | 8294 | 12146 | 63468540 |
Treatment noncompliance | 90.39 | 24.19 | 58 | 8278 | 37267 | 63443419 |
Cough | 86.64 | 24.19 | 145 | 8191 | 292598 | 63188088 |
Atelectasis | 82.56 | 24.19 | 45 | 8291 | 21438 | 63459248 |
Off label use | 82.23 | 24.19 | 233 | 8103 | 674229 | 62806457 |
Nonspecific reaction | 77.07 | 24.19 | 23 | 8313 | 2269 | 63478417 |
Aggression | 70.84 | 24.19 | 42 | 8294 | 23456 | 63457230 |
Lung disorder | 67.93 | 24.19 | 60 | 8276 | 62201 | 63418485 |
Rib fracture | 67.10 | 24.19 | 40 | 8296 | 22557 | 63458129 |
Sputum increased | 62.87 | 24.19 | 20 | 8316 | 2439 | 63478247 |
Drug reaction with eosinophilia and systemic symptoms | 59.14 | 24.19 | 43 | 8293 | 33793 | 63446893 |
Illness | 54.95 | 24.19 | 48 | 8288 | 49011 | 63431675 |
Distal intestinal obstruction syndrome | 52.71 | 24.19 | 12 | 8324 | 406 | 63480280 |
Wheezing | 51.34 | 24.19 | 63 | 8273 | 95532 | 63385154 |
Forced expiratory volume decreased | 49.14 | 24.19 | 20 | 8316 | 4948 | 63475738 |
Pancreatic failure | 46.84 | 24.19 | 13 | 8323 | 990 | 63479696 |
Bronchiectasis | 46.43 | 24.19 | 28 | 8308 | 16114 | 63464572 |
Impaired quality of life | 45.13 | 24.19 | 26 | 8310 | 13757 | 63466929 |
Infection | 42.27 | 24.19 | 93 | 8243 | 229080 | 63251606 |
Transplant | 40.30 | 24.19 | 11 | 8325 | 787 | 63479899 |
Sinus disorder | 40.19 | 24.19 | 30 | 8306 | 24523 | 63456163 |
Agranulocytosis | 39.56 | 24.19 | 30 | 8306 | 25104 | 63455582 |
Pneumonia | 39.05 | 24.19 | 140 | 8196 | 456627 | 63024059 |
Pulmonary haemorrhage | 39.03 | 24.19 | 19 | 8317 | 7162 | 63473524 |
Anxiety | 37.56 | 24.19 | 86 | 8250 | 217455 | 63263231 |
Pathogen resistance | 34.98 | 24.19 | 17 | 8319 | 6381 | 63474305 |
Dyspnoea | 33.54 | 24.19 | 173 | 8163 | 661140 | 62819546 |
Heart rate increased | 32.28 | 24.19 | 50 | 8286 | 94188 | 63386498 |
Productive cough | 31.27 | 24.19 | 40 | 8296 | 63168 | 63417518 |
Drug resistance | 30.96 | 24.19 | 25 | 8311 | 22908 | 63457778 |
Atrial fibrillation | 30.73 | 24.19 | 55 | 8281 | 116581 | 63364105 |
Chest discomfort | 30.45 | 24.19 | 53 | 8283 | 109916 | 63370770 |
Drug ineffective | 29.63 | 24.19 | 58 | 8278 | 1044707 | 62435979 |
Asthma | 26.05 | 24.19 | 54 | 8282 | 127507 | 63353179 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Infective pulmonary exacerbation of cystic fibrosis | 907.10 | 23.74 | 208 | 4940 | 6593 | 34945190 |
Cystic fibrosis | 355.34 | 23.74 | 75 | 5073 | 1583 | 34950200 |
Lung transplant | 307.43 | 23.74 | 69 | 5079 | 1955 | 34949828 |
Death | 140.38 | 23.74 | 226 | 4922 | 397823 | 34553960 |
Hospitalisation | 125.57 | 23.74 | 87 | 5061 | 56815 | 34894968 |
Eosinophilia | 95.21 | 23.74 | 55 | 5093 | 26167 | 34925616 |
Pulmonary function test decreased | 89.69 | 23.74 | 32 | 5116 | 4943 | 34946840 |
Cystic fibrosis respiratory infection suppression | 87.70 | 23.74 | 17 | 5131 | 228 | 34951555 |
Haemoptysis | 80.60 | 23.74 | 55 | 5093 | 34951 | 34916832 |
Pseudomonas infection | 79.35 | 23.74 | 38 | 5110 | 12344 | 34939439 |
Respiratory failure | 65.20 | 23.74 | 80 | 5068 | 108492 | 34843291 |
Rash maculo-papular | 54.56 | 23.74 | 40 | 5108 | 28411 | 34923372 |
Sputum increased | 53.35 | 23.74 | 18 | 5130 | 2352 | 34949431 |
Cystic fibrosis related diabetes | 49.04 | 23.74 | 10 | 5138 | 176 | 34951607 |
Infection | 48.20 | 23.74 | 63 | 5085 | 90852 | 34860931 |
Productive cough | 46.54 | 23.74 | 41 | 5107 | 37772 | 34914011 |
Hepatic cytolysis | 46.27 | 23.74 | 28 | 5120 | 14468 | 34937315 |
Pathogen resistance | 45.71 | 23.74 | 24 | 5124 | 9458 | 34942325 |
Leukocytosis | 42.04 | 23.74 | 32 | 5116 | 24033 | 34927750 |
Off label use | 41.17 | 23.74 | 145 | 5003 | 419379 | 34532404 |
Infective exacerbation of bronchiectasis | 40.44 | 23.74 | 10 | 5138 | 431 | 34951352 |
Lung disorder | 39.49 | 23.74 | 36 | 5112 | 34660 | 34917123 |
Drug reaction with eosinophilia and systemic symptoms | 35.14 | 23.74 | 33 | 5115 | 32979 | 34918804 |
Rash morbilliform | 34.46 | 23.74 | 14 | 5134 | 3073 | 34948710 |
Distal intestinal obstruction syndrome | 32.28 | 23.74 | 8 | 5140 | 348 | 34951435 |
Toxic epidermal necrolysis | 31.81 | 23.74 | 26 | 5122 | 21620 | 34930163 |
Forced expiratory volume decreased | 30.60 | 23.74 | 13 | 5135 | 3190 | 34948593 |
Condition aggravated | 28.60 | 23.74 | 77 | 5071 | 192119 | 34759664 |
Cough | 27.38 | 23.74 | 65 | 5083 | 150075 | 34801708 |
Cystic fibrosis hepatic disease | 23.97 | 23.74 | 4 | 5144 | 21 | 34951762 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Infective pulmonary exacerbation of cystic fibrosis | 2039.29 | 21.05 | 450 | 10874 | 12401 | 79720663 |
Cystic fibrosis | 565.17 | 21.05 | 127 | 11197 | 3753 | 79729311 |
Lung transplant | 405.04 | 21.05 | 100 | 11224 | 4461 | 79728603 |
Eosinophilia | 243.91 | 21.05 | 122 | 11202 | 45223 | 79687841 |
Pulmonary function test decreased | 239.82 | 21.05 | 74 | 11250 | 7563 | 79725501 |
Haemoptysis | 222.41 | 21.05 | 123 | 11201 | 55876 | 79677188 |
Death | 216.17 | 21.05 | 328 | 10996 | 566186 | 79166878 |
Hospitalisation | 205.14 | 21.05 | 141 | 11183 | 94095 | 79638969 |
Bacterial disease carrier | 184.23 | 21.05 | 43 | 11281 | 1503 | 79731561 |
Bronchial secretion retention | 164.42 | 21.05 | 48 | 11276 | 4056 | 79729008 |
Cystic fibrosis respiratory infection suppression | 148.90 | 21.05 | 29 | 11295 | 415 | 79732649 |
Pseudomonas infection | 138.75 | 21.05 | 65 | 11259 | 20838 | 79712226 |
Superinfection | 130.97 | 21.05 | 42 | 11282 | 4860 | 79728204 |
Sinus operation | 112.13 | 21.05 | 32 | 11292 | 2493 | 79730571 |
Bronchospasm | 102.44 | 21.05 | 56 | 11268 | 24803 | 79708261 |
Sputum increased | 100.98 | 21.05 | 34 | 11290 | 4579 | 79728485 |
Scoliosis | 99.14 | 21.05 | 38 | 11286 | 7426 | 79725638 |
Respiratory failure | 94.17 | 21.05 | 122 | 11202 | 180789 | 79552275 |
Drug reaction with eosinophilia and systemic symptoms | 92.32 | 21.05 | 75 | 11249 | 64169 | 79668895 |
Sleep disorder due to a general medical condition | 87.40 | 21.05 | 42 | 11282 | 14235 | 79718829 |
Off label use | 81.17 | 21.05 | 297 | 11027 | 906918 | 78826146 |
Distal intestinal obstruction syndrome | 78.71 | 21.05 | 19 | 11305 | 768 | 79732296 |
Treatment noncompliance | 75.04 | 21.05 | 61 | 11263 | 52207 | 79680857 |
Nonspecific reaction | 73.03 | 21.05 | 23 | 11301 | 2509 | 79730555 |
Forced expiratory volume decreased | 70.06 | 21.05 | 30 | 11294 | 7784 | 79725280 |
Atelectasis | 67.09 | 21.05 | 47 | 11277 | 32210 | 79700854 |
Pathogen resistance | 66.63 | 21.05 | 35 | 11289 | 14307 | 79718757 |
Cough | 66.59 | 21.05 | 155 | 11169 | 366634 | 79366430 |
Pancreatic failure | 65.02 | 21.05 | 19 | 11305 | 1609 | 79731455 |
Infective exacerbation of bronchiectasis | 63.81 | 21.05 | 16 | 11308 | 758 | 79732306 |
Lung disorder | 63.01 | 21.05 | 67 | 11257 | 80490 | 79652574 |
Rash maculo-papular | 55.51 | 21.05 | 53 | 11271 | 56025 | 79677039 |
Wheezing | 51.97 | 21.05 | 73 | 11251 | 116591 | 79616473 |
Rib fracture | 51.87 | 21.05 | 38 | 11286 | 27909 | 79705155 |
Bronchiectasis | 49.80 | 21.05 | 34 | 11290 | 22352 | 79710712 |
Productive cough | 49.72 | 21.05 | 62 | 11262 | 88269 | 79644795 |
Pneumonia | 48.89 | 21.05 | 204 | 11120 | 660042 | 79073022 |
Toxic epidermal necrolysis | 45.77 | 21.05 | 43 | 11281 | 44538 | 79688526 |
Impaired quality of life | 42.21 | 21.05 | 26 | 11298 | 14360 | 79718704 |
Drug resistance | 41.97 | 21.05 | 40 | 11284 | 42173 | 79690891 |
Cystic fibrosis related diabetes | 41.76 | 21.05 | 9 | 11315 | 217 | 79732847 |
Transplant | 41.30 | 21.05 | 12 | 11312 | 996 | 79732068 |
Aggression | 40.92 | 21.05 | 43 | 11281 | 50915 | 79682149 |
Illness | 40.51 | 21.05 | 41 | 11283 | 46470 | 79686594 |
Sinus disorder | 40.46 | 21.05 | 30 | 11294 | 22434 | 79710630 |
Pneumonia pseudomonal | 38.03 | 21.05 | 18 | 11306 | 5893 | 79727171 |
Hepatic cytolysis | 37.51 | 21.05 | 31 | 11293 | 27120 | 79705944 |
Agranulocytosis | 36.16 | 21.05 | 38 | 11286 | 44992 | 79688072 |
Toxicity to various agents | 35.88 | 21.05 | 8 | 11316 | 421532 | 79311532 |
Dyspnoea | 33.60 | 21.05 | 222 | 11102 | 856803 | 78876261 |
Leukocytosis | 31.95 | 21.05 | 35 | 11289 | 43420 | 79689644 |
Rash morbilliform | 31.41 | 21.05 | 16 | 11308 | 6134 | 79726930 |
Chest discomfort | 29.07 | 21.05 | 62 | 11262 | 137982 | 79595082 |
Acute generalised exanthematous pustulosis | 28.76 | 21.05 | 22 | 11302 | 17232 | 79715832 |
Disease complication | 28.63 | 21.05 | 14 | 11310 | 4923 | 79728141 |
Pneumothorax | 28.46 | 21.05 | 27 | 11297 | 28296 | 79704768 |
Fatigue | 28.26 | 21.05 | 56 | 11268 | 929671 | 78803393 |
Toxic skin eruption | 27.80 | 21.05 | 24 | 11300 | 22269 | 79710795 |
Asthma | 26.54 | 21.05 | 59 | 11265 | 135036 | 79598028 |
Tracheostomy | 26.36 | 21.05 | 9 | 11315 | 1263 | 79731801 |
Blood alkaline phosphatase increased | 25.64 | 21.05 | 38 | 11286 | 63626 | 79669438 |
Sputum discoloured | 24.30 | 21.05 | 22 | 11302 | 21721 | 79711343 |
Heart rate increased | 24.02 | 21.05 | 53 | 11271 | 120671 | 79612393 |
Joint swelling | 23.51 | 21.05 | 6 | 11318 | 288640 | 79444424 |
Anxiety | 23.38 | 21.05 | 83 | 11241 | 248429 | 79484635 |
Diarrhoea | 22.68 | 21.05 | 58 | 11266 | 880431 | 78852633 |
Pain in extremity | 22.29 | 21.05 | 12 | 11312 | 364526 | 79368538 |
Cystic fibrosis hepatic disease | 21.95 | 21.05 | 4 | 11320 | 39 | 79733025 |
Bronchopulmonary aspergillosis allergic | 21.80 | 21.05 | 10 | 11314 | 3051 | 79730013 |
Peripheral swelling | 21.21 | 21.05 | 6 | 11318 | 269611 | 79463453 |
None
Source | Code | Description |
---|---|---|
ATC | J01DF01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Monobactams |
FDA CS | M0014030 | Monobactams |
FDA EPC | N0000175493 | Monobactam Antibacterial |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:50696 | PBP3 inhibitor |
CHEBI has role | CHEBI:88188 | allergenic drug |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Septicemia due to Escherichia coli | indication | 9323009 | |
Infection due to Pseudomonas aeruginosa | indication | 11218009 | |
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Pneumonia due to Pseudomonas | indication | 41381004 | |
Peritonitis | indication | 48661000 | |
Lower respiratory tract infection | indication | 50417007 | |
Pneumonia due to Escherichia coli | indication | 51530003 | |
Klebsiella cystitis | indication | 60867007 | |
Urinary tract infectious disease | indication | 68566005 | |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Infection due to Escherichia coli | indication | 71057007 | |
Bacterial infection due to Serratia | indication | 71120004 | |
Rhinoscleroma | indication | 72409005 | DOID:11336 |
Endometritis | indication | 78623009 | DOID:1002 |
Septicemia due to Serratia | indication | 82091000 | |
Female genital tract infection | indication | 125585007 | |
Infectious disease of abdomen | indication | 128070006 | |
Infection due to Enterobacteriaceae | indication | 128945009 | |
Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
Proteus pneumonia | indication | 195888009 | |
Bacterial peritonitis | indication | 197171003 | |
Proteus septicemia | indication | 300986008 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Proteus urinary tract infection | indication | 301012009 | |
Bacterial urinary infection | indication | 312124009 | |
Sepsis due to Pseudomonas | indication | 448813005 | |
Sepsis due to Gram negative bacteria | indication | 449082003 | |
Gram-Negative Aerobic Bacillary Pneumonia | indication | ||
Serratia Urinary Tract Infection | indication | ||
E. Coli Pelvic Inflammatory Disease | indication | ||
Enterobacter Pneumonia | indication | ||
Citrobacter Urinary Tract Infection | indication | ||
Skin and Skin Structure Proteus Infection | indication | ||
Skin and Skin Structure Pseudomonas Aeruginosa Infection | indication | ||
Haemophilus Influenzae Bronchitis | indication | ||
E. Coli Bronchitis | indication | ||
Respiratory Cystic Fibrosis with Pseudomonas aeruginosa Colonization | indication | ||
Skin and Skin Structure Serratia Infection | indication | ||
Inflammatory Disease of Female Pelvic Organs | indication | ||
Proteus Pelvic Inflammatory Disease | indication | ||
E. Coli Endometritis | indication | ||
Enterobacter Cloacae Bronchitis | indication | ||
Serratia Bronchitis | indication | ||
Pseudomonas Aeruginosa Bronchitis | indication | ||
Citrobacter Peritonitis | indication | ||
Aerobic Gram-Negative Bacteremia | indication | ||
E. Coli Peritonitis | indication | ||
Enterobacter Endometritis | indication | ||
Skin and Skin Structure Citrobacter Infection | indication | ||
Serratia Peritonitis | indication | ||
Enterobacter Pelvic Inflammatory Disease | indication | ||
Klebsiella Endometritis | indication | ||
Pseudomonas Aeruginosa Urinary Tract Infection | indication | ||
Klebsiella Pelvic Inflammatory Disease | indication | ||
Bacterial Exacerbation of Acute Bronchitis | indication | ||
Proteus Bronchitis | indication | ||
Proteus Endometritis | indication | ||
Klebsiella Pneumoniae Peritonitis | indication | ||
Bronchospasm | contraindication | 4386001 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Pseudomembranous enterocolitis | contraindication | 397683000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.44 | acidic |
pKa2 | 2.83 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Penicillin-binding protein 1A | Enzyme | INHIBITOR | IC50 | 5.32 | WOMBAT-PK | CHEMBL | |||
Penicillin-binding protein 1B | Enzyme | INHIBITOR | IC50 | 4.32 | WOMBAT-PK | CHEMBL | |||
Peptidoglycan synthase FtsI | Enzyme | INHIBITOR | IC50 | 5.74 | WOMBAT-PK | CHEMBL | |||
Beta-lactamase | Enzyme | IC50 | 7.49 | CHEMBL | |||||
AmpC | Unclassified | IC50 | 7.22 | CHEMBL | |||||
Efflux transporter; SugE | Transporter | IC50 | 8.22 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 8.22 | CHEMBL | |||||
Beta-lactamase | Enzyme | Ki | 8.15 | CHEMBL | |||||
Beta-lactamase | Enzyme | Ki | 5.52 | CHEMBL | |||||
Penicillin-binding protein 1A | Enzyme | IC50 | 5.48 | CHEMBL | |||||
Beta-lactamase | Enzyme | Ki | 5.70 | CHEMBL |
ID | Source |
---|---|
D00240 | KEGG_DRUG |
827611-49-4 | SECONDARY_CAS_RN |
1272 | RXNORM |
C0004521 | UMLSCUI |
CHEBI:161680 | CHEBI |
T6O | PDB_CHEM_ID |
CHEMBL158 | ChEMBL_ID |
CHEMBL3833340 | ChEMBL_ID |
D001398 | MESH_DESCRIPTOR_UI |
DB00355 | DRUGBANK_ID |
10763 | IUPHAR_LIGAND_ID |
5159 | INN_ID |
G2B4VE5GH8 | UNII |
5742832 | PUBCHEM_CID |
167898 | MMSL |
170132 | MMSL |
2813 | MMSL |
4239 | MMSL |
d00067 | MMSL |
373297006 | SNOMEDCT_US |
387386004 | SNOMEDCT_US |
409132008 | SNOMEDCT_US |
409133003 | SNOMEDCT_US |
69918003 | SNOMEDCT_US |
734461007 | SNOMEDCT_US |
90614001 | SNOMEDCT_US |
4017762 | VANDF |
4037186 | VANDF |
002807 | NDDF |
013342 | NDDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
AZACTAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-2560 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | NDA | 21 sections |
AZACTAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-2560 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | NDA | 21 sections |
AZACTAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-2560 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | NDA | 21 sections |
AZACTAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-2570 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | NDA | 21 sections |
AZACTAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-2570 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | NDA | 21 sections |
AZACTAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-2570 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | NDA | 21 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-0829 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 23 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-0830 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 23 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-401 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-401 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-401 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-401 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-401 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-401 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-402 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-402 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-402 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-402 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-402 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-402 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 24 sections |